Other financial information 8446 Annual Report 2011 Annual Report 2011 15 03 2012 16:14 Page 125 c Annual Report 2011 Shire plc Annual Report 2011 125 Other financial information Quarterly results of operations unaudited The following table presents summarized unaudited quarterly results for the years to December 31, 2011 and 2010: Q1 Q2 Q3 Q4 2011 $M $M $M $M Total revenues 972.7 1,062.9 1,086.1 1,142.2 Operating income 266.5 283.3 255.4 304.0 Net income attributable to Shire plc 211.3 205.5 192.9 255.3 Earnings per sharebasic 38.5 37.2 35.0 46.4 Earnings per sharediluted 37.0 35.9 33.9 44.4 Q1 Q2 Q3 Q4 2010 $M $M $M $M Total revenues 816.2 849.4 874.3 931.2 Operating income 217.8 224.4 155.8 196.1 Net income attributable to Shire plc 165.9 160.5 96.3 165.3 Earnings per sharebasic 30.5 29.4 17.6 30.1 Earnings per sharediluted 29.7 28.6 17.3 29.4 Non GAAP measures Divestments, reorganizations and discontinued operations: These Non GAAP financial measures are used by Shires managementgains and losses on the sale of non-core assets: to make operating decisions because they facilitate internal costs associated with restructuring and reorganization activities: comparisons of Shires performance to historical results and to competitors results.
Shires Remuneration Committee uses certain termination costs: and key Non GAAP measures when assessing the performance and income losses from discontinued operations.
compensation of employees, including Shires Executive Directors.
Depreciation, which is included in Cost of product sales, R&D and The Non GAAP measures are presented in this Annual Report, SG&A costs in our US GAAP results, has been separately disclosed as Shires management believe that they will provide investors for the presentation of 2011, 2010 and 2009 Non GAAP earnings.
with a means of evaluating, and an understanding of how Shires management evaluates, Shires performance and results on a Cash generation represents net cash provided by operating activities, comparable basis that is not otherwise apparent on a US GAAP excluding up front and milestone payments for in-licensed and acquired basis, since many non-recurring, infrequent or non-cash items products, tax and interest payments.
that Shires management believe are not indicative of the core performance of the business may not be excluded when preparing Free cash flow represents net cash provided by operating activities, financial measures under US GAAP.
excluding up front and milestone payments for in-licensed and acquired products, but including capital expenditure in the ordinary These Non GAAP measures should not be considered in isolation course of business.
from, as substitutes for, or superior to, financial measures prepared in accordance with US GAAP.
Non GAAP EBITDA represents Non GAAP operating income before depreciation.
Where applicable the following items, including their tax effect, have been excluded from 2011, 2010 and 2009 Non GAAP earnings.
Non GAAP ROIC aims to measure true underlying economic performance of the Group, by making a number of adjustments to Amortization and asset impairments: ROIC as derived from Shires Non GAAP financial results including: intangible asset amortization and impairment charges: and adding back to Non GAAP operating income all R&D expenses, other than temporary impairment of investments.
intangible asset impairment charges and operating lease costs incurred in the period: Acquisitions and integration activities: upfront payments and milestones in respect of in-licensed andcapitalizing on the Groups balance sheet historic, cumulative R&D, acquired products: IPR&D, intangible asset impairment charges and operating lease costs which previously have been expensed: costs associated with acquisitions, including transaction costs, fair value adjustments on contingent consideration and acquireddeducting from Non GAAP operating income an amortization charge inventory: for the above capitalized costs, based on the estimated commercial lives of the relevant products: costs associated with the integration of companies: and excluding the income statement and balance sheet impact of nonnon controlling interests in consolidated variable interest entities.
operating assets such as surplus cash and non-strategic investments : and taxing the resulting adjusted operating income at the underlying Non GAAP tax rate.
8446 Annual Report 2011 Annual Report 2011 15 03 2012 16:14 Page 126 126 Shire plc Annual Report 2011 Shire plc Annual Repo Other financial information A reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP is presented below.
Non GAAP reconciliation 2011 US GAAP Adjustments Non GAAP Divestments, Amortization Acquisitions reorganizations December 31, and asset and integration and discontinued Reclassify December 31, a b c d 2011 impairments activities operations depreciation 2011 Year to, $M $M $M $M $M $M Total revenues 4,263.4 4,263.4 Costs and expenses Cost of product sales 588.1 11.0 11.3 33.2 532.6 R&D 770.7 16.0 25.2 729.5 SG&A 1,751.4 165.0 63.1 1,523.3 Loss on sale of product rights 6.0 6.0 Reorganization costs 24.3 24.3 Integration and acquisition costs 13.7 13.7 Depreciation 121.5 121.5 Total operating expenses 3,154.2 181.0 24.7 41.6 2,906.9 Operating income 1,109.2 181.0 24.7 41.6 1,356.5 Interest income 1.9 1.9 Interest expense 39.1 39.1 Other income expense, net 18.1 2.4 23.5 3.0 Total other expense, net 19.1 2.4 23.5 40.2 Income before income taxes and equity in earnings of equity method investees 1,090.1 183.4 24.7 18.1 1,316.3 Income taxes 227.6 58.7 8.3 2.7 291.9 Equity in earnings of equity method investees, net of tax 2.5 2.5 Net income 865.0 124.7 16.4 20.8 1,026.9 Impact of convertible debt, net of tax 33.6 33.6 Numerator for diluted EPS 898.6 124.7 16.4 20.8 1,060.5 Weighted average number of shares millions diluted 595.4 595.4 Diluted earnings per ADS 452.7 62.7 8.4 10.5 534.3 The following items are included in Adjustments: a Amortization and asset impairments: Impairment of intangible assets $16.0 million, amortization of intangible assets relating to intellectual property rights acquired $165.0 million, impairment of available for sale securities $2.4 million, and tax effect of adjustments: b Acquisitions and integration activities: Unwind of ABH inventory fair value adjustment $11.0 million, costs associated with acquisition and integration of ABH $13.6 million and integration of Movetis $8.3 million, less adjustment to contingent consideration payable for EQUASYM $8.2 million, and tax effect of adjustments: c Divestments, reorganizations and discontinued operations: Accelerated depreciation $6.6 million and dual running costs $4.7 million on the transfer of manufacturing from Owings Mills to a third party, remeasurement of DAYTRANA contingent consideration to fair value $6.0 million, reorganization costs $24.3 million on the transfer of manufacturing from Owings Mills to a third party and the establishment of an international commercial hub in Switzerland, gain on disposal of investment in Vertex $23.5 million, and tax effect of adjustments: and d Depreciation: Depreciation of $121.5 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.
Other financial information 8446 Annual Report 2011 Annual Report 2011 15 03 2012 16:14 Page 127 c Annual Report 2011 Shire plc Annual Report 2011 127 Non GAAP reconciliation 2010 US GAAP Adjustments Non GAAP Divestments, Amortization Acquisitions reorganizations December 31, and asset and integration and discontinued Reclassify December 31, a b c d 2010 impairments activities operations depreciation 2010 Year to, $M $M $M $M $M $M Total revenues 3,471.1 3,471.1 Costs and expenses Cost of product sales 463.4 30.4 12.4 420.6 R&D 661.5 45.0 19.0 597.5 SG&A 1,526.3 176.2 62.1 1,288.0 Gain on sale of product rights 16.5 16.5 Reorganization costs 34.3 34.3 Integration and acquisition costs 8.0 8.0 Depreciation 93.5 93.5 Total operating expenses 2,677.0 176.2 53.0 48.2 2,399.6 Operating income 794.1 176.2 53.0 48.2 1,071.5 Interest income 2.4 2.4 Interest expense 35.1 35.1 Other income expense, net 7.9 11.1 3.2 Total other expense, net 24.8 11.1 35.9 Income before income taxes and equity in earnings of equity method investees 769.3 176.2 53.0 37.1 1,035.6 Income taxes 182.7 38.9 3.5 13.5 238.6 Equity in earnings of equity method investees, net of tax 1.4 1.4 Net income 588.0 137.3 49.5 23.6 798.4 Impact of convertible debt, net of tax 33.5 33.5 Numerator for diluted EPS 621.5 137.3 49.5 23.6 831.9 Weighted average number of shares millions diluted 590.3 590.3 Diluted earnings per ADS 315.9 69.7 25.1 12.0 422.7 The following items are included in Adjustments: a Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired $133.5 million, impairment charge to record DAYTRANA assets at fair value less costs to sell $42.7 million and tax effect of adjustments: b Acquisitions and integration activities: up front payment to Acceleron $45.0 million, acquisition costs $8.0 million primarily related to the Movetis acquisition and tax effect of adjustments: c Divestments, reorganizations and discontinued operations: Accelerated depreciation $25.7 million and dual running costs $4.7 million on the transfer of manufacturing from Owings Mills to a third party, gain on sale of non-core product rights $6.1 million, remeasurement of DAYTRANA contingent consideration to fair value $10.4 million, reorganization costs $34.3 million on the transfer of manufacturing from Owings Mills to a third party and the establishment of an international commercial hub in Switzerland, gain on disposal of the investment in ViroChem $11.1 million, and tax effect of adjustments: and d Depreciation: Depreciation of $93.5 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.
8446 Annual Report 2011 Annual Report 2011 15 03 2012 16:15 Page 128 128 Shire plc Annual Report 2011 Shire plc Annual Repo Other financial information Non GAAP reconciliation 2009 US GAAP Adjustments Non GAAP Divestments, Amortization Acquisitions reorganizations December 31, and asset and integration and discontinued Reclassify December 31, a b c d 2009 impairments activities operations depreciation 2009 Year to, $M $M $M $M $M $M Total revenues 3,007.7 3,007.7 Costs and expenses Cost of product sales 388.0 1.9 12.0 9.8 364.3 R&D 639.9 36.9 62.9 15.5 523.0 SG&A 1,342.6 136.9 67.7 1,138.0 Gain on sale of product rights 6.3 6.3 Reorganization costs 12.7 12.7 Integration and acquisition costs 10.6 10.6 Depreciation 93.0 93.0 Total operating expenses 2,387.5 136.9 51.0 81.3 2,118.3 Operating income 620.2 136.9 51.0 81.3 889.4 Interest income 1.9 1.9 Interest expense 39.8 39.8 Other income expense, net 60.7 55.2 5.5 Total other income expense, net 22.8 55.2 32.4 Income before income taxes and equity in losses of equity method investees 643.0 136.9 51.0 26.1 857.0 Income taxes 138.5 38.8 16.2 20.7 214.2 Equity in losses of equity method investees, net of tax 0.7 0.7 Our markets Income from continuing operations, Argentina net of tax 503.8 98.1 34.8 5.4 642.1 Australia Loss from discontinued operations 12.4 12.4 Belgium Net income 491.4 98.1 34.8 17.8 642.1 Brazil Add: Net loss attributable to non controlling Canada interest in subsidiaries 0.2 0.2 Colombia Czech Republic Net income attributable to Shire plc 491.6 98.1 34.8 17.8 642.3 Denmark 1 Impact of convertible debt, net of tax 33.6 33.6 Finland France Numerator for diluted EPS 491.6 131.7 34.8 17.8 675.9 Germany Weighted average number of shares Greece 1 millions diluted 548.0 33.1 581.1 Ireland Diluted earnings per ADS 269.1 52.6 18.0 9.2 348.9 Italy Japan 1 The impact of convertible debt, net of tax has a dilutive effect on a Non GAAP basis.
The following items are included in Adjustments: a Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired $136.9 million and tax effect of adjustment: b Acquisitions and integration activities: Inventory fair value adjustment related to the acquisition of Jerini $1.9 million : payment on amendment of INTUNIV in-license agreement $36.9 million : IPR&D charge in respect of Jerini $1.6 million, costs associated with the integration and acquisition of Jerini and EQUASYM $10.6 million : and tax effect of adjustments: c Divestments, reorganizations and discontinued operations: Accelerated depreciation $12.0 million and reorganization costs $12.7 million for the transition of manufacturing from Owings Mills to a third party: costs associated with the agreement to terminate Womens Health products with Duramed $62.9 million : gain on disposal of non-core product rights $6.3 million : gain on disposal of investment in ViroChem $55.2 million : discontinued operations in respect of non-core Jerini operations $12.4 million, and tax effect of adjustments: and d Depreciation: Depreciation of $93.0 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.
